Insilico Medicine announces advancement of its preclinical candidate for USP1 synthetic lethality target to IND-enabling studies for various oncological disorders
New York, April 13, 2022/PRNewswire/-- Insilico Medicine(“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company today announced that the ...
